Trastuzumab in a Neo-Adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms TRAIN
- 07 Jun 2017 Biomarkers information updated
- 01 Mar 2017 Results reporting the efficacy and toxicity of weekly paclitaxel-trastuzumab-carboplatin as neo-adjuvant treatment, published in the European Journal of Cancer.
- 10 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.